
Opinion|Videos|September 28, 2023
Case Presentation: A 71-Year-Old Woman with Relapsed/Refractory Multiple Myeloma (RRMM)
Author(s)Ajai Chari, MD, PhD
Ajai Chari, MD, presents the case of a 71-year-old woman with relapsed/refractory multiple myeloma who showed signs of disease progression after four lines of therapy and was initiated on a recently FDA-approved bispecific antibody, talquetamab.
Advertisement
Episodes in this series

Now Playing
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Updated HARMONi Analysis Shows Consistent OS Benefit With Ivonescimab in EGFRm Lung Cancer
2
FDA Accepts NDA for Daraxonrasib in Metastatic Pancreatic Cancer
3
How Inherited BRCA Mutations Shape Breast Cancer's Genomic Behavior and Point Toward a New Treatment Paradigm
4
Community Clinical Trials and the Lung Cancer Pipeline
5




























